Clinical trial · Observational
Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration
NCT02226666CI-TRIAL-00025477completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to prospectively compare the physiologic response of patients who receive either intravenous gadoxetic acid (Eovist) or intravenous gadobenate dimeglumine (MultiHance).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Tumor | Liver Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI with Eovist | Drug | — | UNRESOLVED |
| MRI with Multihance | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients having MRI with Eovist
- description
- Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
- interventionNames
- Drug: MRI with Eovist
- label
- Patients having MRI with Multihance
- description
- Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
- interventionNames
- Drug: MRI with Multihance
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years old and older * Patients scheduled for MRI examination at the University of Michigan hospital * Patients receiving either MultiHance or Eovist contrast agents during their clinical MRI examination Exclusion Criteria: * Patients under 18 years of age * Patients who will not receive MultiHance or Eovist as part of their clinical MRI examination
References
Publications (0)
Data not yet available
No reference posted for this study.